Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias
Open Access
- 19 April 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (8) , 4249
Abstract
Polyglutamine spinocerebellar ataxias (PolyQ SCAs) are a group of 6 rare autosomal dominant diseases, which arise from an abnormal CAG repeat expansion in the coding region of their causative gene. These neurodegenerative ataxic disorders are characterized by progressive cerebellar degeneration, which translates into progressive ataxia, the main clinical feature, often accompanied by oculomotor deficits and dysarthria. Currently, PolyQ SCAs treatment is limited only to symptomatic mitigation, and no therapy is available to stop or delay the disease progression, which culminates with death. Over the last years, many promising gene therapy approaches were investigated in preclinical studies and could lead to a future treatment to stop or delay the disease development. Here, we summed up the most promising of these therapies, categorizing them in gene augmentation therapy, gene silencing strategies, and gene edition approaches. While several of the reviewed strategies are promising, there is still a gap from the preclinical results obtained and their translation to clinical studies. However, there is an increase in the number of approved gene therapies, as well as a constant development in their safety and efficacy profiles. Thus, it is expected that in a near future some of the promising strategies reviewed here could be tested in a clinical setting and if successful provide hope for SCAs patients.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (ALG-01- 0145-FEDER-29480)
- French Muscular Dystrophy Association (22424)
- Ataxia UK (ZUNIALGA)
This publication has 118 references indexed in Scilit:
- Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyondThe Lancet Neurology, 2010
- Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivoMolecular Therapy, 2009
- miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesisNature Neuroscience, 2008
- RNA toxicity is a component of ataxin-3 degeneration in DrosophilaNature, 2008
- Lentivector‐mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxiaEMBO Reports, 2008
- The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7Proceedings of the National Academy of Sciences, 2008
- Suppression of basal autophagy in neural cells causes neurodegenerative disease in miceNature, 2006
- Loss of autophagy in the central nervous system causes neurodegeneration in miceNature, 2006
- RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxiaNature Medicine, 2004
- Sequence‐dependent and independent inhibition specific for mutant ataxin‐3 by small interfering RNAAnnals of Neurology, 2004